Athenex

Athenex company information, Employees & Contact Information

Explore related pages

Related company profiles:

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Company Details

Employees
82
Address
1001 Main Street,
Phone
(716)427-2950
Email
in****@****nex.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Buffalo, New York
Looking for a particular Athenex employee's phone or email?

Athenex Questions

News

Athenex Receives FDA Complete Response Letter for Oral - GlobeNewswire

Athenex Receives FDA Complete Response Letter for Oral GlobeNewswire

Athenex Announces a Reverse Stock Split - Yahoo Finance

Athenex Announces a Reverse Stock Split Yahoo Finance

Type A Meeting Between FDA and Athenex Discusses Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer - Oncology Nursing News

Type A Meeting Between FDA and Athenex Discusses Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer Oncology Nursing News

Athenex files for bankruptcy, seeks buyer for natural killer T-cell therapy unit - Fierce Biotech

Athenex files for bankruptcy, seeks buyer for natural killer T-cell therapy unit Fierce Biotech

Athenex assets sold in bankruptcy auction; top executives dismissed - WGRZ

Athenex assets sold in bankruptcy auction; top executives dismissed WGRZ

Oraxol Gets Orphan Drug Designation for Angiosarcoma - Medical Professionals Reference

Oraxol Gets Orphan Drug Designation for Angiosarcoma Medical Professionals Reference

Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations - ACS Publications

Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations ACS Publications

FDA Issues Response Letter for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer - CancerNetwork

FDA Issues Response Letter for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer CancerNetwork

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis - The New England Journal of Medicine

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis The New England Journal of Medicine

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update - GlobeNewswire

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update GlobeNewswire

ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex - The Business Journals

ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex The Business Journals

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis - Yahoo Finance

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis Yahoo Finance

Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor - ACS Publications

Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor ACS Publications

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process - GlobeNewswire

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process GlobeNewswire

Athenex assets sold in bankruptcy auction; top executives dismissed - The Business Journals

Athenex assets sold in bankruptcy auction; top executives dismissed The Business Journals

Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase) - GlobeNewswire

Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase) GlobeNewswire

Athenex Announces $225 Million Loan Agreement with Oaktree - GlobeNewswire

Athenex Announces $225 Million Loan Agreement with Oaktree GlobeNewswire

Athenex Announces Sale of Revenues from U.S. and European - GlobeNewswire

Athenex Announces Sale of Revenues from U.S. and European GlobeNewswire

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy - GlobeNewswire

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy GlobeNewswire

Athenex Pharma Solutions, an Athenex, Inc. Company, - GlobeNewswire

Athenex Pharma Solutions, an Athenex, Inc. Company, GlobeNewswire

Top Athenex Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant